Position Statement: Atypical Femoral Fracture from the Korean Society for Bone and Mineral Research in 2023

참고문헌 (57)

1. Khosla S, "Benefits and risks of bisphosphonate therapy for osteoporosis", J Clin Endocrinol Metab, 97, pp.2272~2282 (2012)[DOI]
2. Reszka AA, "Bisphosphonate mechanism of action", Curr Rheumatol Rep, 5, pp.65~74 (2003)[DOI]
3. Odvina CV, "Severely suppressed bone turnover : a potential complication of alendronate therapy", J Clin Endocrinol Metab, 90, pp.1294~1301 (2005)[DOI]
4. 김하영, "Healthcare Costs of Osteoporotic Fracture in Korea: Information from the National Health Insurance Claims Database, 2008-2011", 대한골대사학회지, 24(2), pp.125~133 (2017), 대한골대사학회[DOI]
5. 이화복, "National Healthcare Budget Impact Analysis of the Treatment for Osteoporosis and Fractures in Korea", 대한골대사학회지, 20(1), pp.17~23 (2013), 대한골대사학회[DOI]
6. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 25, pp.2267~2294 (2010)[DOI]
7. Shane E, "Atypical subtrochanteric and diaphyseal femoral fractures : second report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 29, pp.1~23 (2014)[DOI]
8. 양규현, "Atypical Femoral Fracture: 2015 Position Statement of the Korean Society for Bone and Mineral Research", 대한골대사학회지, 22(3), pp.87~91 (2015), 대한골대사학회[DOI]
9. LeBlanc ES, "Evaluating atypical features of femur fractures : how change in radiological criteria influenced incidence and demography of atypical femur fractures in a community setting", J Bone Miner Res, 32, pp.2304~2314 (2017)[DOI]
10. 안승희, "Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea", 대한골대사학회지, 27(4), pp.281~290 (2020), 대한골대사학회
11. Girgis CM, "Population and treatment-based incidence estimates of atypical fractures", Med J Aust, 194, pp.666~ (2011)[DOI]
12. Dell RM, "Incidence of atypical nontraumatic diaphyseal fractures of the femur", J Bone Miner Res, 27, pp.2544~2550 (2012)[DOI]
13. Mahjoub Z, "Incidence and characteristics of atypical femoral fractures : clinical and geometrical data", J Bone Miner Res, 31, pp.767~776 (2016)[DOI]
14. Lo JC, "The association of race", ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy, 2016, pp.85, 142~147
15. Lee YK, "Atypical subtrochanteric fractures in Korean hip fracture study", Osteoporos Int, 28, pp.2853~2858 (2017)[DOI]
16. Gertz BJ, "Clinical pharmacology of alendronate sodium", Osteoporos Int, 3(Suppl 3), pp.S13~S16 (1993)[DOI]
17. Khan SA, "Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis", J Bone Miner Res, 12, pp.1700~1707 (1997)[DOI]
18. Gedmintas L, "Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis", J Bone Miner Res, 28, pp.1729~1737 (2013)[DOI]
19. Black DM, "Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates", N Engl J Med, 383, pp.743~753 (2020)[DOI]
20. Donnelly E, "Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures", J Bone Miner Res, 27, pp.672~678 (2012)[DOI]
21. Durchschlag E, "Bone material properties in trabecular bone from human iliac crest biopsies after 3-and 5-year treatment with risedronate", J Bone Miner Res, 21, pp.1581~1590 (2006)[DOI]
22. Mashiba T, "Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles", Bone, 28, pp.524~531 (2001)[DOI]
23. Tjhia CK, "Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects", Bone, 49, pp.1279~1289 (2011)[DOI]
24. Austin DC, "Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab", Acta Orthop, 88, pp.351~353 (2017)[DOI]
25. Bone HG, "The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis : results from the FREEDOM extension", J Clin Endocrinol Metab, 98, pp.4483~4492 (2013)[DOI]
26. Selga J, "Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab : case report and literature review", Osteoporos Int, 27, pp.827~832 (2016)[DOI]
27. Haider IT, "Influence of geometry on proximal femoral shaft strains : implications for atypical femoral fracture", Bone, 110, pp.295~303 (2018)[DOI]
28. Silverman S, "Bisphosphonate-related atypical femoral fracture : managing a rare but serious complication", Cleve Clin J Med, 85, pp.885~893 (2018)[DOI]
29. Marshall RA, "Imaging features and management of stress, atypical, and pathologic fractures", Radiographics, 38, pp.2173~2192 (2018)[DOI]
30. Fang C, "Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing : a cautionary tale from 2 cases", Geriatr Orthop Surg Rehabil, 5, pp.14~17 (2014)[DOI]
31. van de Laarschot DM, "Screening for atypical femur fractures using extended femur scans by DXA", J Bone Miner Res, 32, pp.1632~1639 (2017)[DOI]
32. Adler RA, "Managing osteoporosis in patients on long-term bisphosphonate treatment : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 31, pp.16~35 (2016)[DOI]
33. 임건일, "Pathogenesis, Management and Prevention of Atypical Femoral Fractures", 대한골대사학회지, 22(1), pp.1~8 (2015), 대한골대사학회[DOI]
34. Byung-Ho Yoon, "Does Teriparatide Improve Fracture Union?: A Systematic Review", 대한골대사학회지, 27(3), pp.167~174 (2020), 대한골대사학회[DOI]
35. 임군일, "Effect of Teriparatide on Healing of Atypical Femoral Fractures: A Systemic Review", 대한골대사학회지, 22(4), pp.183~189 (2015), 대한골대사학회
36. Murphy CM, "PTH(1-34)treatment increases bisphosphonate turnover in fracture repair in rats", J Bone Miner Res, 30, pp.1022~1029 (2015)[DOI]
37. Pietrogrande L, "Teriparatide in the treatment of non-unions : scientific and clinical evidences", Injury, 44(Suppl 1), pp.S54~S57 (2013)[DOI]
38. Lee YK, "Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases", Osteoporos Int, 23, pp.2897~2900 (2012)[DOI]
39. Lee YK, "Predicting need for fixation of atypical femoral fracture", J Clin Endocrinol Metab, 98, pp.2742~2745 (2013)[DOI]
40. Watts NB, "Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates", J Bone Miner Res, 32, pp.1027~1033 (2017)[DOI]
41. Chiang CY, "Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy", Bone, 52, pp.360~365 (2013)[DOI]
42. van de Laarschot DM, "Medical management of patients after atypical femur fractures : a systematic review and recommendations from the european calcified tissue society", J Clin Endocrinol Metab, 105, pp.1682~1699 (2020)[DOI]
43. Ha YC, "Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?", Clin Orthop Relat Res, 468, pp.3393~3398 (2010)[DOI]
44. Neviaser AS, "Low-energy femoral shaft fractures associated with alendronate use", J Orthop Trauma, 22, pp.346~350 (2008)[DOI]
45. 이범석, "대퇴골 비전형 골절: 일반 골절과 다른 점은?", 대한골절학회지, 31(4), pp.159~164 (2018), 대한골절학회[DOI]
46. Abrahamsen B, "Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures : a register-based national cohort analysis", J Clin Endocrinol Metab, 95, pp.5258~5265 (2010)[DOI]
47. Prasarn ML, "Bisphosphonate-associated femur fractures have high complication rates with operative fixation", Clin Orthop Relat Res, 470, pp.2295~2301 (2012)[DOI]
48. Lim HS, "Factors associated with increased healing time in complete femoral fractures after long-term bisphosphonate therapy", J Bone Joint Surg Am, 98, pp.1978~1987 (2016)[DOI]
49. Lee KJ, "Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture : a multicenter retrospective study", Injury, 48, pp.941~945 (2017)[DOI]
50. 이경재, "Surgical Treatment of the Atypical Femoral Fracture: Overcoming Femoral Bowing", Hip and Pelvis, 30(4), pp.202~209 (2018), 대한고관절학회[DOI]
51. Weil YA, "The outcome of surgically treated femur fractures associated with long-term bisphosphonate use", J Trauma, 71, pp.186~190 (2011)[DOI]
52. Park JH, "Surgical tips of intramedullary nailing in severely bowed femurs in atypical femur fractures : simulation with 3D printed model", Injury, 47, pp.1318~1324 (2016)[DOI]
53. Kim JW, "Surgical outcomes of intramedullary nailing for diaphyseal atypical femur fractures : is it safe to modify a nail entry in bowed femur?", Arch Orthop Trauma Surg, 137, pp.1515~1522 (2017)[DOI]
54. Park YC, "Intramedullary nailing for atypical femoral fracture with excessive anterolateral bowing", J Bone Joint Surg Am, 99, pp.726~735 (2017)[DOI]
55. Giusti A, "Atypical fractures of the femur and bisphosphonate therapy : a systematic review of case", case series studies, 2010, pp.47, 169~180
56. Lo JC, "Clinical correlates of atypical femoral fracture", Bone, 51, pp.181~184 (2012)[DOI]
57. 이영균, "Low Positive Predictive Value of Bone Scan to Predict Impending Complete Fracture among Incomplete Atypical Femoral Fracture", Journal of Korean Medical Science, 33(22), pp.1~6 (2018), 대한의학회

관련 논문AI추천